Biofrontera Inc. Files 8-K with Regulatory Disclosures

TL;DR

Biofrontera filed an 8-K on 10/23/25 - check for updates.

AI Summary

Biofrontera Inc. filed an 8-K on October 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware with its principal executive offices in Woburn, Massachusetts, is in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates important updates and disclosures from Biofrontera Inc. to the SEC, which could affect investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate, significant operational changes.

Key Numbers

• 001-40943 — SEC File Number (Identifies the company's filing with the SEC.)
• 47-3765675 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Biofrontera Inc. (company) — Registrant
• October 23, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Woburn, Massachusetts (location) — Address of principal executive offices
• 001-40943 (filing_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar
• $11 million — frontera AG, backed by an investment of $11 million led by existing investors. The full tex

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 16KB
• ex99-1_001.jpg (GRAPHIC) — 11KB
• 0001493152-25-019006.txt ( ) — 289KB
• bfri-20251023.xsd (EX-101.SCH) — 4KB
• bfri-20251023_def.xml (EX-101.DEF) — 26KB
• bfri-20251023_lab.xml (EX-101.LAB) — 36KB
• bfri-20251023_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 7KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights No The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On October 23, 2025, Biofrontera Inc. issued a press release announcing the closing of its restructuring and asset purchase agreement with Biofrontera AG, backed by an investment of $11 million led by existing investors. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Current Report is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. Item 9.01 Financial Statements and Exhibits. 99.1 Press release dated October 23, 2025 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. October 23, 2025 (Date) Biofrontera Inc. (Registrant) /s/ E Fred Leffler, III E Fred Leffler, III Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR